Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.67 |
| ▸ | ESRRA | P11474 | 6/20 | 0.62 |
| ▸ | AR | P10275 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | FDPS | P14324 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.46 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17955067 | 0.86 | TTR (0.81) | TTRALDH1A1TSHRFDPSMAPT | |
| SCHEMBL19131768 | 0.85 | TTR (0.47) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL26936583 | 0.85 | TTR (0.79) | TTRALDH1A1TSHRFDPSMAPT | |
| SCHEMBL29965683 | 0.84 | ESRRA (0.63) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL28889415 | 0.84 | ESRRA (0.63) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL3692375 | 0.84 | AR (0.48) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL6500589 | 0.82 | AR (0.67) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL2380622 | 0.82 | ESRRA (0.64) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL2380981 | 0.82 | ESRRA (0.64) | TTRESRRAARALDH1A1TSHR | |
| SCHEMBL27670275 | 0.82 | TTR (0.74) | TTRARALDH1A1TSHRFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116789620-B | Aryl-containing saturated gamma-butyrolactone compound, preparation method thereof and application thereof in resisting plant viruses | 西北农林科技大学 | 2024-09-10 | — | — | CN | disclosed |
| CN-116789620-A | Aryl-containing saturated gamma-butyrolactone compound, preparation method thereof and application thereof in resisting plant viruses | 西北农林科技大学 | 2023-09-22 | — | — | CN | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-14 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-08-02 | — | — | US | disclosed |
| EP-2450352-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040951-A9 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | TTR 3006/4885ESRRA 2/4885AR 13/4885 |
| US-20120196864-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | BRCA1, ESRRA, NR5A1 | TTR 3006/4885ESRRA 2/4885AR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.